SOD Cancer Research Results

SOD, superoxide dismutase: Click to Expand ⟱
Source:
Type:
SOD, or superoxide dismutase, is an important antioxidant enzyme that plays a crucial role in protecting cells from oxidative stress. It catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide.
SOD Isoforms: There are three main isoforms of SOD:
SOD1 (cytosolic): Often found to be overexpressed in certain tumors, which may help cancer cells survive in oxidative environments.
SOD2 (mitochondrial): Plays a critical role in protecting mitochondria from oxidative damage. Its expression can be upregulated in some cancers, contributing to tumor growth and resistance to therapy.
SOD3 (extracellular): Its role in cancer is less well understood, but it may have implications in the tumor microenvironment and metastasis.
The expression levels of SOD can serve as a prognostic indicator in some cancers. For example, high levels of SOD expression have been associated with poor prognosis in certain types of tumors, potentially due to their role in promoting tumor cell survival and resistance to therapies.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
5396- Ash,    Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology
- Review, Var, NA
selectivity↑, ROS↑, Apoptosis↑, ChemoSen↑, RadioS↑, NF-kB↓, ER-α36↓, P53↑, *ROS∅, γH2AX↑, DNAdam↑, MMP↓, XIAP↓, IAP1↓, survivin↓, SOD↓, Dose↝, IL6↓, TNF-α↓, COX2↓, p‑Akt↓, NOTCH1↓, FOXO↑, Casp↑, MMP2↓, CSCs↓, *ROS↓, *SOD2↑, chemoP↑, ChemoSen↑, RadioS↑,
2652- CAP,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
chemoPv↑, AntiCan↑, ROS↑, TumCG↓, ROS↑, MMP↑, Apoptosis↑, TumCCA↑, JNK↑, SOD↓, Catalase↓, GPx↓, other↓, SIRT1↓, NADPH↑, FOXO3↑,
4913- DSF,    Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies
- Review, Var, NA
Apoptosis↑, tumCV↑, eff↑, toxicity↓, antiNeop↑, ChemoSen↑, RadioS↑, OS↑, ROS↑, SOD↓, MMP1↓, eff↑, Half-Life↓,
4914- DSF,  immuno,    Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies
- Review, Var, NA
AntiTum↑, eff↑, ALDH↓, Dose↝, RadioS↑, angioG↓, TumMeta↓, BioAv↝, ROS↑, DNAdam↑, P-gp↓, CSCs↓, EMT↓, Imm↑, SOD↓, MAPK↓, NF-kB↓, ChemoSen↑, eff↑, toxicity↝, BioAv↑, *Inflam↓, Sepsis↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,
5115- JG,    Natural Products to Fight Cancer: A Focus on Juglans regia
- Review, Var, NA
Casp3↑, Casp9↑, MMP↓, AR↓, PSA↓, E-cadherin↑, N-cadherin↓, Vim↓, Akt↓, GSK‐3β↓, EMT↑, TumCI↓, MMP9↓, VEGF↓, MMP2↓, TumCCA↑, ROS↑, Apoptosis↑, GSH↓, Catalase↓, SOD↓, GPx↓, DNAdam↑, γH2AX↑, eff↑, BAX↑, Fas↑, Pin1↓,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT/TERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1↓, Hif1a↓, LC3II↑, Beclin-1↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,

Showing Research Papers: 1 to 11 of 11

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 5,   CYP1A1↓, 1,   GPx↓, 4,   GSH↓, 4,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   lipid-P↑, 1,   NQO1↓, 1,   NRF2↓, 3,   PYCR1↓, 1,   ROS↓, 1,   ROS↑, 12,   SOD↓, 11,   SOD2↓, 1,   Trx1↑, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   BOK↑, 1,   CDC2↓, 1,   CDC25↓, 1,   FGFR1↓, 3,   MMP↓, 5,   MMP↑, 1,   mtDam↑, 2,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   ALAT↓, 1,   CAIX↓, 1,   cMyc↓, 4,   Glycolysis↓, 1,   LDH↓, 1,   NADPH↑, 2,   PKM2↓, 1,   SIRT1↓, 2,  

Cell Death ⓘ

Akt↓, 5,   Akt↑, 1,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 6,   BAD↑, 1,   BAX↓, 1,   BAX↑, 4,   Bax:Bcl2↑, 2,   Bcl-2↓, 5,   BID↑, 1,   Casp↑, 1,   Casp1↓, 1,   Casp12↑, 1,   cl‑Casp12↑, 1,   Casp3↑, 7,   Casp8↑, 1,   Casp9↑, 5,   proCasp9↓, 1,   CK2↓, 2,   Cyt‑c↑, 4,   DR5↑, 3,   FADD↑, 1,   Fas↑, 4,   FasL↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 2,   IAP1↓, 1,   JNK↑, 1,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 1,   MDM2↓, 1,   p‑MDM2↓, 1,   NAIP↓, 1,   NOXA↑, 1,   p27↑, 1,   p38↑, 1,   p‑p38↑, 1,   PUMA↑, 1,   survivin↓, 1,   Telomerase↓, 2,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

H3↓, 1,   H4↓, 1,   other↓, 1,   tumCV↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   Beclin-1↑, 3,   BNIP3↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3II↓, 1,   LC3II↑, 3,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   P53↑, 4,   PARP↑, 2,   cl‑PARP↑, 1,   PCNA↓, 1,   γH2AX↑, 3,  

Cell Cycle & Senescence ⓘ

CDK2↓, 5,   CDK4↓, 4,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   CycD3↓, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CD34↓, 1,   cFos↑, 1,   CSCs↓, 3,   EMT↓, 6,   EMT↑, 1,   ERK↑, 1,   p‑ERK↓, 1,   FGF↓, 1,   FGFR2↓, 1,   FOXO↑, 1,   FOXO3↑, 2,   Gli↓, 1,   GSK‐3β↓, 1,   HDAC↓, 2,   HDAC1↓, 1,   HDAC3↓, 1,   IGF-1↓, 1,   miR-34a↑, 1,   mTOR↓, 2,   NOTCH↓, 1,   NOTCH1↓, 2,   PI3K↓, 5,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 1,   p‑Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 2,   STAT6↓, 1,   p‑STAT6↓, 1,   TumCG↓, 1,   tyrosinase↓, 1,  

Migration ⓘ

Akt2↓, 1,   AXL↓, 1,   Ca+2↑, 2,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 4,   ER-α36↓, 1,   FAK↓, 3,   ITGB1↓, 1,   Ki-67↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 1,   MMP2↓, 6,   MMP9↓, 4,   N-cadherin↓, 4,   PDGF↓, 1,   Rac1↓, 1,   Rho↓, 1,   Snail↓, 2,   TIMP1↑, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCMig↑, 1,   TumCP↓, 2,   TumMeta↓, 1,   Twist↓, 2,   Tyro3↓, 1,   uPA↓, 1,   Vim↓, 4,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↑, 1,   EGFR↑, 1,   p‑EGFR↓, 1,   Hif1a↓, 2,   VEGF↓, 6,  

Barriers & Transport ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 3,   ICAM-1↓, 1,   IKKα↓, 1,   IL1↓, 1,   IL2↑, 1,   IL6↓, 4,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 7,   p‑p65↓, 1,   PD-1↓, 1,   PSA↓, 1,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↑, 8,   Dose↝, 2,   eff↑, 6,   eff↝, 1,   Half-Life↓, 1,   RadioS↑, 7,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AR↓, 2,   AST↓, 1,   CEA↓, 1,   EGFR↑, 1,   p‑EGFR↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 4,   Ki-67↓, 1,   LDH↓, 1,   NSE↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   antiNeop↑, 1,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 2,   chemoPv↑, 2,   ChemoSideEff↓, 1,   OS↑, 1,   Pin1↓, 1,   toxicity↓, 1,   toxicity↝, 1,   TumW↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 243

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 2,   lipid-P↓, 2,   NRF2↑, 1,   ROS↓, 3,   ROS∅, 1,   SOD↑, 3,   SOD2↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDHA↑, 1,  

Cell Death ⓘ

Casp3↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   eff↑, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

neuroP↑, 2,  
Total Targets: 28

Scientific Paper Hit Count for: SOD, superoxide dismutase
3 Luteolin
2 Disulfiram
2 Ferulic acid
1 Apigenin (mainly Parsley)
1 Ashwagandha(Withaferin A)
1 Capsaicin
1 immunotherapy
1 Juglone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:298  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page